The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis

With the recent successful targeting of B lymphocytes in patients with multiple sclerosis (MS), treatment with anti-CD20 monoclonal antibodies (mAbs) may represent a promising managemental approach, particularly for those with relapsing/remitting MS (RRMS). A network meta-analysis was conducted base...

Descripción completa

Detalles Bibliográficos
Autores principales: Asha, Mohammad Z.I., Al-Asaad, Yousef, Khalil, Sundos F.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411244/
https://www.ncbi.nlm.nih.gov/pubmed/34505112
http://dx.doi.org/10.1016/j.ibneur.2021.08.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411244/
https://www.ncbi.nlm.nih.gov/pubmed/34505112
http://dx.doi.org/10.1016/j.ibneur.2021.08.003

Ejemplares similares